Viewing Study NCT00354003



Ignite Creation Date: 2024-05-05 @ 4:56 PM
Last Modification Date: 2024-10-26 @ 9:26 AM
Study NCT ID: NCT00354003
Status: COMPLETED
Last Update Posted: 2019-04-03
First Post: 2006-07-17

Brief Title: The Study of the Impact of Disclosing Imaging Study Information to Trial Participants
Sponsor: Institute for Neurodegenerative Disorders
Organization: Institute for Neurodegenerative Disorders

Study Overview

Official Title: Impact of Disclosure of Dopamine Transporter Imaging Studies in PD Clinical Trials
Status: COMPLETED
Status Verified Date: 2019-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The overall goal of the study is to evaluate how research participants in Parkinson Disease studies that include brain imaging with a dopamine transporter ligand choose to receive the imaging data and what is the impact of the imaging data information on the management of their symptoms
Detailed Description: Research participants who previously underwent ß-CIT imaging will be contacted by the staff at IND to enquire whether they would like to receive their ß-CIT scan data After signing a Research Participant Information and Consent Form all research participants will be asked to complete a questionnaire prior to receipt of their imaging data Those research participants requesting imaging data will be sent their data by IND and may review their data with IND by phone and or with their study investigator All research participants will be asked to respond to a second questionnaire after receiving their imaging data and to a third study questionnaire approximately six weeks following receipt of their imaging data

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None